{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:03:06Z","timestamp":1793329386181,"version":"4.5.0"},"reference-count":195,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41581-026-01081-1","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:39:03Z","timestamp":1778578743000},"page":"541-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-neutrophil cytoplasmic antibody-associated vasculitis: biological insights and biomarker-guided disease management"],"prefix":"10.1038","volume":"22","author":[{"given":"Marilina","family":"Antonelou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashif Jamil","family":"Anwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9255-9092","authenticated-orcid":false,"given":"Alan D.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"1081_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0272-6386(00)70196-X","volume":"35","author":"M Haas","year":"2000","unstructured":"Haas, M., Spargo, B. H., Wit, E. J. & Meehan, S. M. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am. J. Kidney Dis. 35, 433\u2013447 (2000).","journal-title":"Am. J. Kidney Dis."},{"key":"1081_CR2","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/rheumatology\/keac623","volume":"62","author":"Chevet","year":"2023","unstructured":"Chevet et al. Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice. Rheumatology 62, 1787\u20131803 (2023).","journal-title":"Rheumatology"},{"key":"1081_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","volume":"403","author":"A Kronbichler","year":"2024","unstructured":"Kronbichler, A., Bajema, I. M., Bruchfeld, A., Kirsztajn, G. M. & Stone, J. H. Diagnosis and management of ANCA-associated vasculitis. Lancet 403, 683\u2013698 (2024).","journal-title":"Lancet"},{"key":"1081_CR4","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/bmj.281.6244.836","volume":"281","author":"AJ Pinching","year":"1980","unstructured":"Pinching, A. J. et al. Relapses in Wegener\u2019s granulomatosis: the role of infection. Br. Med. J. 281, 836\u2013838 (1980).","journal-title":"Br. Med. J."},{"key":"1081_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkab018","volume":"5","author":"C King","year":"2021","unstructured":"King, C. et al. Predicting relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic review and meta-analysis. Rheumatol. Adv. Pract. 5, rkab018 (2021).","journal-title":"Rheumatol. Adv. Pract."},{"key":"1081_CR6","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/ard.2009.109389","volume":"69","author":"MA Little","year":"2010","unstructured":"Little, M. A. et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum. Dis. 69, 1036\u20131043 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1081_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S0272-6386(04)00944-8","volume":"44","author":"R Nair","year":"2004","unstructured":"Nair, R., Bell, J. M. & Walker, P. D. Renal biopsy in patients aged 80 years and older. Am. J. Kidney Dis. 44, 618\u2013626 (2004).","journal-title":"Am. J. Kidney Dis."},{"key":"1081_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/ndt\/12.3.418","volume":"12","author":"FP Schena","year":"1997","unstructured":"Schena, F. P. Survey of the Italian registry of renal biopsies. frequency of the renal diseases for 7 consecutive years. the Italian Group of Renal Immunopathology. Nephrol. Dial. Transpl. 12, 418\u2013426 (1997).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1081_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103139","volume":"21","author":"C Boud\u2019hors","year":"2022","unstructured":"Boud\u2019hors, C. et al. Histopathological prognostic factors in ANCA-associated glomerulonephritis. Autoimmun. Rev. 21, 103139 (2022).","journal-title":"Autoimmun. Rev."},{"key":"1081_CR10","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1681\/ASN.2020071074","volume":"32","author":"I Boudhabhay","year":"2021","unstructured":"Boudhabhay, I. et al. Reappraisal of renal arteritis in ANCA-associated vasculitis: clinical characteristics, pathology, and outcome. J. Am. Soc. Nephrol. 32, 2362\u20132374 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR11","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","volume":"41","author":"AD Booth","year":"2003","unstructured":"Booth, A. D. et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am. J. Kidney Dis. 41, 776\u2013784 (2003).","journal-title":"Am. J. Kidney Dis."},{"key":"1081_CR12","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000274","volume":"35","author":"S Bate","year":"2024","unstructured":"Bate, S. et al. The improved kidney risk score in ANCA-associated vasculitis for clinical practice and trials. J. Am. Soc. Nephrol. 35, 335 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR13","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/ndt\/gfae018","volume":"39","author":"B Sachez-Alamo","year":"2024","unstructured":"Sachez-Alamo, B. et al. Long-term outcome of kidney function in patients with ANCA-associated vasculitis. Nephrol. Dial. Transpl. 39, 1483\u20131493 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1081_CR14","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2010050477","volume":"21","author":"AE Berden","year":"2010","unstructured":"Berden, A. E. et al. Histopathologic classification of ANCA-associated glomerulonephritis. J. Am. Soc. Nephrol. 21, 1628\u20131636 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR15","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08290813","volume":"9","author":"T Lee","year":"2014","unstructured":"Lee, T. et al. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin. J. Am. Soc. Nephrol. 9, 905 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1081_CR16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.kint.2018.07.020","volume":"94","author":"SR Brix","year":"2018","unstructured":"Brix, S. R. et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 94, 1177\u20131188 (2018).","journal-title":"Kidney Int."},{"key":"1081_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae125","volume":"17","author":"M Stella","year":"2024","unstructured":"Stella, M. et al. The value of the current histological scores and classifications of ANCA glomerulonephritis in predicting long-term outcome. Clin. Kidney J. 17, sfae125 (2024).","journal-title":"Clin. Kidney J."},{"key":"1081_CR18","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.kint.2020.04.061","volume":"99","author":"PG Tan","year":"2021","unstructured":"Tan, P. G., O\u2019Brien, J., Pusey, C. D. & McAdoo, S. P. Validation of the ANCA renal risk score in a London cohort: potential impact of treatment on prediction outcome. Kidney Int. 99, 488\u2013489 (2021).","journal-title":"Kidney Int."},{"key":"1081_CR19","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1681\/ASN.2021060771","volume":"33","author":"D Nezam","year":"2022","unstructured":"Nezam, D. et al. Kidney histopathology can predict kidney function in ANCA-associated vasculitides with acute kidney injury treated with plasma exchange. s. J. Am. Soc. Nephrol. 33, 628\u2013637 (2022).","journal-title":"s. J. Am. Soc. Nephrol."},{"key":"1081_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102424","volume":"19","author":"B Brilland","year":"2020","unstructured":"Brilland, B. et al. Complement alternative pathway in ANCA-associated vasculitis: two decades from bench to bedside. Autoimmun. Rev. 19, 102424 (2020).","journal-title":"Autoimmun. Rev."},{"key":"1081_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/039463201202500133","volume":"25","author":"A Gigante","year":"2012","unstructured":"Gigante, A. et al. Clinical and histological outcome predictors in renal limited pauci-immune crescentic glomerulonephritis: a single centre experience. Int. J. Immunopathol. Pharmacol. 25, 287\u2013292 (2012).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"1081_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52525-w","volume":"15","author":"J Engesser","year":"2024","unstructured":"Engesser, J. et al. Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis. Nat. Commun. 15, 8220 (2024).","journal-title":"Nat. Commun."},{"key":"1081_CR23","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20243gtd3bss","volume":"27","author":"B Brilland","year":"2025","unstructured":"Brilland, B. et al. Identification of kidney transcripts associated with prognosis in ANCA-associated glomerulonephritis: SA-PO755. J. Am. Soc. Nephrol. 27, 166. https:\/\/doi.org\/10.1681\/ASN.20243gtd3bss (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1046\/j.1523-1755.2001.00492.x","volume":"59","author":"GS Hill","year":"2001","unstructured":"Hill, G. S. et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 59, 304\u2013316 (2001).","journal-title":"Kidney Int."},{"key":"1081_CR25","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/ndt\/gfu042","volume":"29","author":"Z Hruskova","year":"2014","unstructured":"Hruskova, Z. et al. Repeat protocol renal biopsy in ANCA-associated renal vasculitis. Nephrol. Dial. Transpl. 29, 1728\u20131732 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1081_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/ndt\/17.4.587","volume":"17","author":"HA Hauer","year":"2002","unstructured":"Hauer, H. A. et al. Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies. Nephrol. Dial. Transpl. 17, 587\u2013596 (2002).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1081_CR27","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1016\/j.ekir.2023.07.021","volume":"8","author":"F Aqeel","year":"2023","unstructured":"Aqeel, F., Xu, L. & Geetha, D. Repeat kidney biopsies in anti-neutrophil cytoplasmic autoantibody-associated vasculitis: clinical and histologic progression. Kidney Int. Rep. 8, 2146\u20132149 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1081_CR28","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020050652","volume":"32","author":"B Ginley","year":"2021","unstructured":"Ginley, B. et al. Automated computational detection of interstitial fibrosis, tubular atrophy, and glomerulosclerosis. J. Am. Soc. Nephrol. 32, 837 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1053\/j.ajkd.2019.02.016","volume":"74","author":"T Chen","year":"2019","unstructured":"Chen, T. et al. Prediction and risk stratification of kidney outcomes in IgA nephropathy. Am. J. Kidney Dis. 74, 300\u2013309 (2019).","journal-title":"Am. J. Kidney Dis."},{"key":"1081_CR30","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.kint.2020.07.046","volume":"99","author":"FP Schena","year":"2021","unstructured":"Schena, F. P. et al. Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy. Kidney Int. 99, 1179\u20131188 (2021).","journal-title":"Kidney Int."},{"key":"1081_CR31","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.144779","volume":"6","author":"M Zimmermann","year":"2021","unstructured":"Zimmermann, M. Deep learning-based molecular morphometrics for kidney biopsies. JCI Insight 6, e144779. https:\/\/doi.org\/10.1172\/jci.insight.144779 (2021).","journal-title":"JCI Insight"},{"key":"1081_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ekir.2024.11.005","volume":"10","author":"MAC Wester Trejo","year":"2024","unstructured":"Wester Trejo, M. A. C. et al. Explainability of a deep learning-based classification model for antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int. Rep. 10, 457\u2013465 (2024).","journal-title":"Kidney Int. Rep."},{"key":"1081_CR33","doi-asserted-by":"publisher","first-page":"e762","DOI":"10.1016\/S2665-9913(24)00187-5","volume":"6","author":"K Gisslander","year":"2024","unstructured":"Gisslander, K. et al. Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort. Lancet Rheumatol. 6, e762\u2013e770 (2024).","journal-title":"Lancet Rheumatol."},{"key":"1081_CR34","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2012-201750","volume":"72","author":"A Mahr","year":"2013","unstructured":"Mahr, A. et al. Revisiting the classification of clinical phenotypes of anti-neutrophilcytoplasmic antibody-associated vasculitis: a cluster analysis. Ann. Rheum. Dis. 72, 1003\u20131010 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1081_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70009","volume":"7","author":"H Lindberg","year":"2025","unstructured":"Lindberg, H. et al. In-depth analysis of disease manifestations in antineutrophil cytoplasmic antibody-associated vasculitides identifies distinct clinical phenotypes. ACR Open. Rheumatol. 7, e70009 (2025).","journal-title":"ACR Open. Rheumatol."},{"key":"1081_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84627-6","volume":"11","author":"H Watanabe","year":"2021","unstructured":"Watanabe, H. et al. Exploratory classification of clinical phenotypes in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis using cluster analysis. Sci. Rep. 11, 5223 (2021).","journal-title":"Sci. Rep."},{"key":"1081_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165402","volume":"11","author":"A G\u00f6\u00e7ero\u011flu","year":"2016","unstructured":"G\u00f6\u00e7ero\u011flu, A. et al. ANCA-associated glomerulonephritis: risk factors for renal relapse. PLoS ONE 11, e0165402 (2016).","journal-title":"PLoS ONE"},{"key":"1081_CR38","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1681\/ASN.2020030239","volume":"32","author":"Z Zheng","year":"2021","unstructured":"Zheng, Z. et al. Subtyping CKD patients by consensus clustering: the chronic renal insufficiency cohort (CRIC) study. J. Am. Soc. Nephrol. 32, 639\u2013653 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR39","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.2215\/CJN.13121215","volume":"11","author":"RL Amdur","year":"2016","unstructured":"Amdur, R. L. et al. Inflammation and progression of CKD: the CRIC study. Clin. J. Am. Soc. Nephrol. 11, 1546\u20131556 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1081_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2180373","volume":"2018","author":"S Mihai","year":"2018","unstructured":"Mihai, S. et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J. Immunol. Res. 2018, 2180373 (2018).","journal-title":"J. Immunol. Res."},{"key":"1081_CR41","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1681\/ASN.2020111607","volume":"32","author":"ME Grams","year":"2021","unstructured":"Grams, M. E. et al. Proteins associated with risk of kidney function decline in the general population. J. Am. Soc. Nephrol. 32, 2291\u20132302 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR42","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","volume":"403","author":"K Wong","year":"2024","unstructured":"Wong, K. et al. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK national registry of rare kidney diseases (RaDaR) cohort. Lancet 403, 1279\u20131289 (2024).","journal-title":"Lancet"},{"key":"1081_CR43","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/acr.25100","volume":"75","author":"JS Hanberg","year":"2023","unstructured":"Hanberg, J. S. et al. Longitudinal patterns of renal function in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 75, 2190\u20132198 (2023).","journal-title":"Arthritis Care Res."},{"key":"1081_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/ar4066","volume":"14","author":"B Wilde","year":"2012","unstructured":"Wilde, B. et al. Th17 expansion in granulomatosis with polyangiitis (Wegener\u2019s): the role of disease activity, immune regulation and therapy. Arthritis Res. Ther. 14, R227 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"1081_CR45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/art.39814","volume":"69","author":"RJ Pepper","year":"2017","unstructured":"Pepper, R. J. et al. The association of serum calprotectin (S100A8\/S100A9) levels with disease relapses in PR3-ANCA-associated vasculitis. Arthritis Rheumatol. 69, 185\u2013193 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1081_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ekir.2019.10.005","volume":"5","author":"AD Salama","year":"2019","unstructured":"Salama, A. D. Relapse in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. Kidney Int. Rep. 5, 7\u201312 (2019).","journal-title":"Kidney Int. Rep."},{"key":"1081_CR47","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000444925","volume":"43","author":"A Oomatia","year":"2016","unstructured":"Oomatia, A. et al. Prolonged duration of renal recovery following ANCA-associated glomerulonephritis. Am. J. Nephrol. 43, 112\u2013119 (2016).","journal-title":"Am. J. Nephrol."},{"key":"1081_CR48","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.kint.2023.02.029","volume":"103","author":"N Benichou","year":"2023","unstructured":"Benichou, N. et al. Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis. Kidney Int. 103, 1144\u20131155 (2023).","journal-title":"Kidney Int."},{"key":"1081_CR49","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2215\/CJN.04160417","volume":"13","author":"RL Rhee","year":"2018","unstructured":"Rhee, R. L. et al. The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis. Clin. J. Am. Soc. Nephrol. 13, 251\u2013257 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1081_CR50","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1093\/rheumatology\/keab695","volume":"61","author":"GB Chapman","year":"2022","unstructured":"Chapman, G. B. et al. Utility of interval kidney biopsy in ANCA-associated vasculitis. Rheumatology 61, 1966\u20131974 (2022).","journal-title":"Rheumatology"},{"key":"1081_CR51","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.33361","volume":"64","author":"M Walsh","year":"2012","unstructured":"Walsh, M. et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 542\u2013548 (2012).","journal-title":"Arthritis Rheum."},{"key":"1081_CR52","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1159\/000063553","volume":"20","author":"M Girndt","year":"2002","unstructured":"Girndt, M. Humoral immune responses in uremia and the role of IL-10. Blood Purif. 20, 485\u2013488 (2002).","journal-title":"Blood Purif."},{"key":"1081_CR53","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1002\/art.23800","volume":"58","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux, C. et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 58, 2908\u20132918 (2008).","journal-title":"Arthritis Rheum."},{"key":"1081_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7326\/0003-4819-120-1-199401010-00003","volume":"120","author":"CA Stegeman","year":"1994","unstructured":"Stegeman, C. A. et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med. 120, 12\u201317 (1994).","journal-title":"Ann. Intern. Med."},{"key":"1081_CR55","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/art.42843","volume":"76","author":"ML Junek","year":"2024","unstructured":"Junek, M. L. et al. Risk of relapse of antineutrophil cytoplasmic antibody-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids. Arthritis Rheumatol. 76, 1431\u20131438 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1081_CR56","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh, M. et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N. Engl. J. Med. 382, 622\u2013631 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1081_CR57","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/rheumatology\/key260","volume":"58","author":"Wester","year":"2019","unstructured":"Wester et al. Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome. Rheumatology 58, 103\u2013109 (2019).","journal-title":"Rheumatology"},{"key":"1081_CR58","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","unstructured":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N. Engl. J. Med. 352, 351\u2013361 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1081_CR59","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/ard-2021-221800","volume":"82","author":"SR Henderson","year":"2023","unstructured":"Henderson, S. R. et al. Proteinase 3 promotes formation of multinucleated giant cells and granuloma-like structures in patients with granulomatosis with polyangiitis. Ann. Rheum. Dis. 82, 848\u2013856. https:\/\/doi.org\/10.1136\/ard-2021-221800 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1081_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.07.001","volume":"105","author":"A Berti","year":"2019","unstructured":"Berti, A. et al. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. J. Autoimmun. 105, 102302 (2019).","journal-title":"J. Autoimmun."},{"key":"1081_CR61","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/09629350400003100","volume":"13","author":"S Ohlsson","year":"2004","unstructured":"Ohlsson, S., Wieslander, J. & Segelmark, M. Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome? Mediators Inflamm. 13, 275\u2013283 (2004).","journal-title":"Mediators Inflamm."},{"key":"1081_CR62","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez057.024","volume":"58","author":"I Kwame","year":"2019","unstructured":"Kwame, I. et al. 025. Cytokine and chemokine expression in serum and nasal mucosa in granulomatosis with polyangiitis. Rheumatology 58, kez057.024 (2019).","journal-title":"Rheumatology"},{"key":"1081_CR63","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/art.70061","volume":"78","author":"B Lim","year":"2026","unstructured":"Lim, B., Qian, W., Dowling, F., Salama, A. & Smith, R. M. The effect of intranasal niclosamide on nasal symptoms in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 78, 970\u2013975 (2026).","journal-title":"Arthritis Rheumatol."},{"key":"1081_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103438","volume":"23","author":"D Roccatello","year":"2024","unstructured":"Roccatello, D. et al. Might maintenance therapy be discontinued once clinical remission is achieved in ANCA-associated vasculitis? Autoimmun. Rev. 23, 103438 (2024).","journal-title":"Autoimmun. Rev."},{"key":"1081_CR65","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/ndt\/gfaa066","volume":"36","author":"LS van Dam","year":"2020","unstructured":"van Dam, L. S. et al. PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab. Nephrol. Dial. Transpl. 36, 1408\u20131417 (2020).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1081_CR66","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","volume":"76","author":"A Karras","year":"2017","unstructured":"Karras, A. et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann. Rheum. Dis. 76, 1662\u20131668 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1081_CR67","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/rheumatology\/kex281","volume":"56","author":"AAE de Joode","year":"2017","unstructured":"de Joode, A. A. E. et al. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. Rheumatology 56, 1894\u20131901 (2017).","journal-title":"Rheumatology"},{"key":"1081_CR68","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin, L. et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N. Engl. J. Med. 371, 1771\u20131780 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1081_CR69","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra, T. F. et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304, 2381\u20132388 (2010).","journal-title":"JAMA"},{"key":"1081_CR70","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","volume":"359","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux, C. et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 359, 2790\u20132803 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1081_CR71","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1002\/art.34583","volume":"64","author":"RM Smith","year":"2012","unstructured":"Smith, R. M. et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3760\u20133769 (2012).","journal-title":"Arthritis Rheum."},{"key":"1081_CR72","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","volume":"105","author":"J Floege","year":"2024","unstructured":"Floege, J., Jayne, D. R. W., Sanders, J.-S. F., Tesar, V. & Rovin, B. H. KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int. 105, S71\u2013S116 (2024).","journal-title":"Kidney Int."},{"key":"1081_CR73","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ekir.2019.01.004","volume":"4","author":"SL Hogan","year":"2019","unstructured":"Hogan, S. L. et al. Understanding long-term remission off therapy in antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. Rep. 4, 551\u2013560 (2019).","journal-title":"Kidney Int. Rep."},{"key":"1081_CR74","doi-asserted-by":"publisher","unstructured":"Oates, T. Reestablishment of immune tolerance in ANCA-associated vasculitis: defining a cohort with sustained ANCA negativity and drug free clinical remission [Abstract P2_92]. 18th Int. Vasculitis ANCA Workshop https:\/\/doi.org\/10.1093\/rheumatology\/kex133 (2017).","DOI":"10.1093\/rheumatology\/kex133"},{"key":"1081_CR75","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/ (US FDA, 2025)."},{"key":"1081_CR76","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211\u2013220 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1081_CR77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2215\/CJN.06460622","volume":"18","author":"M Casal Moura","year":"2023","unstructured":"Casal Moura, M. et al. Maintenance of remission and risk of relapse in myeloperoxidase-positive ANCA-associated vasculitis with kidney involvement. Clin. J. Am. Soc. Nephrol. 18, 47 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1081_CR78","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/art.40538","volume":"70","author":"H Watanabe","year":"2018","unstructured":"Watanabe, H. et al. Association between reappearance of myeloperoxidase-antineutrophil cytoplasmic antibody and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: subgroup analysis of nationwide prospective cohort studies. Arthritis Rheumatol. 70, 1626\u20131633 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1081_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02221","volume":"10","author":"A von Borstel","year":"2019","unstructured":"von Borstel, A. et al. CD27+CD38hi B cell frequency during remission predicts relapsing disease in granulomatosis with polyangiitis patients. Front. Immunol. 10, 2221 (2019).","journal-title":"Front. Immunol."},{"key":"1081_CR80","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/08916934.2014.914174","volume":"47","author":"N Venhoff","year":"2014","unstructured":"Venhoff, N. et al. Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease. Autoimmunity 47, 401\u2013408 (2014).","journal-title":"Autoimmunity"},{"key":"1081_CR81","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","volume":"51","author":"G Tomasson","year":"2012","unstructured":"Tomasson, G., Grayson, P. C., Mahr, A. D., LaValley, M. & Merkel, P. A. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis \u2014 a meta-analysis. Rheumatology 51, 100\u2013109 (2012).","journal-title":"Rheumatology"},{"key":"1081_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.844112","volume":"9","author":"A Al-Soudi","year":"2022","unstructured":"Al-Soudi, A., Vegting, Y., Klarenbeek, P. L. & Hilhorst, M. L. Do relapses follow ANCA rises? A systematic review and meta-analysis on the value of serial ANCA level evaluation. Front. Med. 9, 844112 (2022).","journal-title":"Front. Med."},{"key":"1081_CR83","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1681\/ASN.2013111233","volume":"26","author":"MJ Kemna","year":"2015","unstructured":"Kemna, M. J. et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J. Am. Soc. Nephrol. 26, 537\u2013542 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1214945","volume":"14","author":"I Wojcik","year":"2023","unstructured":"Wojcik, I. et al. Specific IgG glycosylation differences precede relapse in PR3-ANCA associated vasculitis patients with and without ANCA rise. Front. Immunol. 14, 1214945 (2023).","journal-title":"Front. Immunol."},{"key":"1081_CR85","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1172\/JCI65292","volume":"123","author":"AJ Roth","year":"2013","unstructured":"Roth, A. J. et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J. Clin. Invest. 123, 1773\u20131783 (2013).","journal-title":"J. Clin. Invest."},{"key":"1081_CR86","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1681\/ASN.2010030274","volume":"21","author":"AE Berden","year":"2010","unstructured":"Berden, A. E. et al. Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis. J. Am. Soc. Nephrol. 21, 2169\u20132179 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR87","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/rheumatology\/ket345","volume":"53","author":"J Hao","year":"2014","unstructured":"Hao, J., Wang, C., Gou, S.-J., Zhao, M.-H. & Chen, M. The association between anti-plasminogen antibodies and disease activity in ANCA-associated vasculitis. Rheumatology 53, 300\u2013306 (2014).","journal-title":"Rheumatology"},{"key":"1081_CR88","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.medcli.2023.03.026","volume":"161","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. The role of anti-HMGB1 antibody and anti-moesin antibody in ANCA-associated vasculitis. Med. Clin. 161, 101\u2013106 (2023).","journal-title":"Med. Clin."},{"key":"1081_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102725","volume":"124","author":"R Padoan","year":"2021","unstructured":"Padoan, R. et al. IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis. J. Autoimmun. 124, 102725 (2021).","journal-title":"J. Autoimmun."},{"key":"1081_CR90","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/03009742.2022.2045790","volume":"52","author":"AD Jonasdottir","year":"2023","unstructured":"Jonasdottir, A. D. et al. Pentraxin-3 - a potential biomarker in ANCA-associated vasculitis. Scand. J. Rheumatol. 52, 293\u2013301 (2023).","journal-title":"Scand. J. Rheumatol."},{"key":"1081_CR91","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles, P. et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann. Rheumatic Dis. 77, 1143\u20131149 (2018).","journal-title":"Ann. Rheumatic Dis."},{"key":"1081_CR92","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks, U. et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 369, 417\u2013427 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1081_CR93","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2023-224489","volume":"83","author":"R Zonozi","year":"2024","unstructured":"Zonozi, R. et al. Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial. Ann. Rheum. Dis. 83, 351\u2013359 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1081_CR94","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/art.42388","volume":"75","author":"A Berti","year":"2023","unstructured":"Berti, A. et al. Autoreactive plasmablasts after B cell depletion with rituximab and relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 75, 736\u2013747 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1081_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.803175","volume":"12","author":"J Arnold","year":"2022","unstructured":"Arnold, J. et al. A personalized rituximab retreatment approach based on clinical and B-cell biomarkers in ANCA-associated vasculitis. Front. Immunol. 12, 803175. https:\/\/doi.org\/10.3389\/fimmu.2021.803175 (2022).","journal-title":"Front. Immunol."},{"key":"1081_CR96","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","volume":"170","author":"H Xiao","year":"2007","unstructured":"Xiao, H., Schreiber, A., Heeringa, P., Falk, R. J. & Jennette, J. C. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am. J. Pathol. 170, 52\u201364 (2007).","journal-title":"Am. J. Pathol."},{"key":"1081_CR97","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1681\/ASN.2008050497","volume":"20","author":"A Schreiber","year":"2009","unstructured":"Schreiber, A. et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J. Am. Soc. Nephrol. 20, 289\u2013298 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195680","volume":"13","author":"S Deshayes","year":"2018","unstructured":"Deshayes, S. et al. Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis. PLoS ONE 13, e0195680 (2018).","journal-title":"PLoS ONE"},{"key":"1081_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158871","volume":"11","author":"J-F Augusto","year":"2016","unstructured":"Augusto, J.-F. et al. Low serum complement C3 levels at diagnosis of renal ANCA-associated vasculitis is associated with poor prognosis. PLoS ONE 11, e0158871 (2016).","journal-title":"PLoS ONE"},{"key":"1081_CR100","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.2215\/CJN.02790313","volume":"8","author":"S-J Gou","year":"2013","unstructured":"Gou, S.-J., Yuan, J., Wang, C., Zhao, M.-H. & Chen, M. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin. J. Am. Soc. Nephrol. 8, 1884\u20131891 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1081_CR101","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1016\/j.ekir.2023.08.017","volume":"8","author":"S Almaani","year":"2023","unstructured":"Almaani, S. et al. Urine and plasma complement Ba levels during disease flares in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int. Rep. 8, 2421\u20132427 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1081_CR102","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/cei.13498","volume":"202","author":"S Moiseev","year":"2020","unstructured":"Moiseev, S. et al. The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis. Clin. Exp. Immunol. 202, 394\u2013402 (2020).","journal-title":"Clin. Exp. Immunol."},{"key":"1081_CR103","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/ndt\/gfaa206","volume":"37","author":"M Antonelou","year":"2022","unstructured":"Antonelou, M., Evans, R. D. R., Henderson, S. R. & Salama, A. D. Neutrophils are key mediators in crescentic glomerulonephritis and targets for new therapeutic approaches. Nephrol. Dial. Transplant. 37, 230\u2013238 (2022).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1081_CR104","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nm.1959","volume":"15","author":"K Kessenbrock","year":"2009","unstructured":"Kessenbrock, K. et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15, 623\u2013625 (2009).","journal-title":"Nat. Med."},{"key":"1081_CR105","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/ki.2015.202","volume":"88","author":"KM O\u2019Sullivan","year":"2015","unstructured":"O\u2019Sullivan, K. M. et al. Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. Kidney Int. 88, 1030\u20131046 (2015).","journal-title":"Kidney Int."},{"key":"1081_CR106","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1681\/ASN.2019060618","volume":"31","author":"M Antonelou","year":"2020","unstructured":"Antonelou, M. et al. Therapeutic myeloperoxidase inhibition attenuates neutrophil activation, ANCA-mediated endothelial damage, and crescentic GN. J. Am. Soc. Nephrol. 31, 350\u2013364 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR107","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1681\/ASN.2011030298","volume":"23","author":"Y Hong","year":"2012","unstructured":"Hong, Y. et al. Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles. J. Am. Soc. Nephrol. 23, 49\u201362 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR108","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.kint.2023.03.029","volume":"104","author":"Aendekerk","year":"2023","unstructured":"Aendekerk et al. Assessment of longitudinal serum neutrophil extracellular trap-inducing activity in anti-neutrophil cytoplasmic antibody-associated vasculitis and glomerulonephritis in a prospective cohort using a novel bio-impedance technique. Kidney Int. 104, 151\u2013162 (2023).","journal-title":"Kidney Int."},{"key":"1081_CR109","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003477","volume":"9","author":"X Romand","year":"2023","unstructured":"Romand, X. et al. Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial. RMD Open. 9, e003477 (2023).","journal-title":"RMD Open."},{"key":"1081_CR110","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1097\/01.ASN.0000028642.26222.00","volume":"13","author":"AA Rarok","year":"2002","unstructured":"Rarok, A. A., Stegeman, C. A., Limburg, P. C. & Kallenberg, C. G. M. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J. Am. Soc. Nephrol. 13, 2232\u20132238 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58550-7","volume":"16","author":"M Nishide","year":"2025","unstructured":"Nishide, M. et al. Neutrophil single-cell analysis identifies a type II interferon-related subset for predicting relapse of autoimmune small vessel vasculitis. Nat. Commun. 16, 3581 (2025).","journal-title":"Nat. Commun."},{"key":"1081_CR112","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1002\/art.39153","volume":"67","author":"PC Grayson","year":"2015","unstructured":"Grayson, P. C. et al. Neutrophil-related gene expression and low-density granulocytes associated with disease activity and response to treatment in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 67, 1922\u20131932 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"1081_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41328-0","volume":"14","author":"M Nishide","year":"2023","unstructured":"Nishide, M. et al. Single-cell multi-omics analysis identifies two distinct phenotypes of newly-onset microscopic polyangiitis. Nat. Commun. 14, 5789 (2023).","journal-title":"Nat. Commun."},{"key":"1081_CR114","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.prp.2017.04.011","volume":"213","author":"J Li","year":"2017","unstructured":"Li, J., Yu, Y.-F., Liu, C.-H. & Wang, C.-M. Significance of M2 macrophages in glomerulonephritis with crescents. Pathol. Res. Pract. 213, 1215\u20131220 (2017).","journal-title":"Pathol. Res. Pract."},{"key":"1081_CR115","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1681\/ASN.2015050511","volume":"27","author":"VP O\u2019Reilly","year":"2016","unstructured":"O\u2019Reilly, V. P. et al. Urinary soluble CD163 in active renal vasculitis. J. Am. Soc. Nephrol. 27, 2906\u20132916 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR116","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.2215\/CJN.07210520","volume":"15","author":"Aendekerk","year":"2020","unstructured":"Aendekerk et al. Urinary soluble CD163 and disease activity in biopsy-proven ANCA-associated glomerulonephritis. Clin. J. Am. Soc. Nephrol. 15, 1740\u20131748 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1081_CR117","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1093\/ndt\/gfh487","volume":"19","author":"FWK Tam","year":"2004","unstructured":"Tam, F. W. K. et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol. Dial. Transpl. 19, 2761\u20132768 (2004).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1081_CR118","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/ckj\/sfac257","volume":"16","author":"Anton-Pampols","year":"2023","unstructured":"Anton-Pampols et al. Combining neutrophil and macrophage biomarkers to detect active disease in ANCA vasculitis: a combinatory model of calprotectin and urine CD163. Clin. Kidney J. 16, 693\u2013700 (2023).","journal-title":"Clin. Kidney J."},{"key":"1081_CR119","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/ndt\/gfy018","volume":"34","author":"GJ Dekkema","year":"2019","unstructured":"Dekkema, G. J. et al. Urinary and serum soluble CD25 complements urinary soluble CD163 to detect active renal anti-neutrophil cytoplasmic autoantibody-associated vasculitis: a cohort study. Nephrol. Dial. Transpl. 34, 234\u2013242 (2019).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1081_CR120","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/ndt\/gfy300","volume":"35","author":"SM Moran","year":"2020","unstructured":"Moran, S. M. et al. Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol. Dial. Transpl. 35, 283\u2013291 (2020).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1081_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43358-5","volume":"9","author":"A Droguett","year":"2019","unstructured":"Droguett, A. et al. Gremlin, a potential urinary biomarker of Anca-associated crescentic glomerulonephritis. Sci. Rep. 9, 6867 (2019).","journal-title":"Sci. Rep."},{"key":"1081_CR122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223703","volume":"14","author":"Y Takei","year":"2019","unstructured":"Takei, Y. et al. Urinary activin a is a novel biomarker reflecting renal inflammation and tubular damage in ANCA-associated vasculitis. PLoS ONE 14, e0223703 (2019).","journal-title":"PLoS ONE"},{"key":"1081_CR123","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003579","volume":"10","author":"T Renson","year":"2024","unstructured":"Renson, T. et al. Non-invasive biomarkers of disease activity and organ damage in ANCA-associated vasculitis: a systematic review. RMD Open 10, e003579\u00a0(2024).","journal-title":"RMD Open"},{"key":"1081_CR124","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf086","volume":"18","author":"\u00c1D J\u00f3nasd\u00f3ttir","year":"2025","unstructured":"J\u00f3nasd\u00f3ttir, \u00c1D. et al. Urinary TWEAK reflects disease activity in ANCA-associated vasculitis. Clin. Kidney J. 18, sfaf086 (2025).","journal-title":"Clin. Kidney J."},{"key":"1081_CR125","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12026-015-8761-y","volume":"64","author":"W-D Xu","year":"2016","unstructured":"Xu, W.-D., Zhao, Y. & Liu, Y. Role of the TWEAK\/Fn14 pathway in autoimmune diseases. Immunol. Res. 64, 44\u201350 (2016).","journal-title":"Immunol. Res."},{"key":"1081_CR126","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","volume":"54","author":"F Alberici","year":"2015","unstructured":"Alberici, F. et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology 54, 1153\u20131160 (2015).","journal-title":"Rheumatology"},{"key":"1081_CR127","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/rheumatology\/keu136","volume":"53","author":"SK Todd","year":"2014","unstructured":"Todd, S. K. et al. Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 53, 1693\u20131703 (2014).","journal-title":"Rheumatology"},{"key":"1081_CR128","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.arcmed.2009.04.001","volume":"40","author":"Z Hruskova","year":"2009","unstructured":"Hruskova, Z. et al. Intracellular cytokine production in ANCA-associated vasculitis: low levels of interleukin-10 in remission are associated with a higher relapse rate in the long-term follow-up. Arch. Med. Res. 40, 276\u2013284 (2009).","journal-title":"Arch. Med. Res."},{"key":"1081_CR129","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/art.38916","volume":"67","author":"S Unizony","year":"2015","unstructured":"Unizony, S. et al. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody\u2013associated vasculitis. Arthritis Rheumatol. 67, 535\u2013544 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"1081_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02796-9","volume":"24","author":"Wang","year":"2022","unstructured":"Wang et al. Increased frequency of IgD-CD27hiCD38hi B cells and its association with the renal involvement in ANCA-associated vasculitis. Arthritis Res. Ther. 24, 109 (2022).","journal-title":"Arthritis Res. Ther."},{"key":"1081_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2023.12.116","volume":"56","author":"S Kelly","year":"2024","unstructured":"Kelly, S., Jackson, K. J. L., Peters, T. J., Suan, D. & Goodnow, C. C. Isolation of antigen-specific B cells in ANCA-associated vasculitis; successes and challenges. Pathology 56, S31 (2024).","journal-title":"Pathology"},{"key":"1081_CR132","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41584-018-0065-x","volume":"14","author":"M McClure","year":"2018","unstructured":"McClure, M., Gopaluni, S., Jayne, D. & Jones, R. B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. Nat. Rev. Rheumatol. 14, 580\u2013591 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1081_CR133","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/MAJ.0b013e3182a55ab6","volume":"348","author":"G Xin","year":"2014","unstructured":"Xin, G. et al. Serum B-cell activating factor in myeloperoxiase-antineutrophil cytoplasmic antibodies-associated vasculitis. Am. J. Med. Sci. 348, 25\u201329 (2014).","journal-title":"Am. J. Med. Sci."},{"key":"1081_CR134","first-page":"62","volume":"28","author":"C Schneeweis","year":"2010","unstructured":"Schneeweis, C. et al. Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). Clin. Exp. Rheumatol. 28, 62\u201366 (2010).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1081_CR135","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.it.2011.06.004","volume":"32","author":"Z Liu","year":"2011","unstructured":"Liu, Z. & Davidson, A. BAFF and selection of autoreactive B cells. Trends Immunol. 32, 388\u2013394 (2011).","journal-title":"Trends Immunol."},{"key":"1081_CR136","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.jaci.2016.08.051","volume":"139","author":"F Alberici","year":"2017","unstructured":"Alberici, F. et al. Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis. J. Allergy Clin. Immunol. 139, 1684\u20131687.e10 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1081_CR137","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/art.40802","volume":"71","author":"D Jayne","year":"2019","unstructured":"Jayne, D. et al. Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study. Arthritis Rheumatol. 71, 952\u2013963 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"1081_CR138","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.kint.2024.08.012","volume":"106","author":"CK Cheung","year":"2024","unstructured":"Cheung, C. K. et al. Targeting APRIL in the treatment of glomerular diseases. Kidney Int. 106, 806\u2013818 (2024).","journal-title":"Kidney Int."},{"key":"1081_CR139","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3389\/fimmu.2020.00525","volume":"11","author":"L Shochet","year":"2020","unstructured":"Shochet, L., Holdsworth, S. & Kitching, A. R. Animal models of ANCA associated vasculitis. Front. Immunol. 11, 525(2020).","journal-title":"Front. Immunol."},{"key":"1081_CR140","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2249.1991.tb05647.x","volume":"83","author":"E Brouwer","year":"1991","unstructured":"Brouwer, E. et al. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener\u2019s granulomatosis and clinically related disorders. Clin. Exp. Immunol. 83, 379\u2013386 (1991).","journal-title":"Clin. Exp. Immunol."},{"key":"1081_CR141","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1002\/art.24747","volume":"60","author":"WH Abdulahad","year":"2009","unstructured":"Abdulahad, W. H., Kallenberg, C. G. M., Limburg, P. C. & Stegeman, C. A. Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60, 2830\u20132838 (2009).","journal-title":"Arthritis Rheum."},{"key":"1081_CR142","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.ekir.2023.01.013","volume":"8","author":"J Sonnemann","year":"2023","unstructured":"Sonnemann, J. et al. Urinary T cells identify renal antineutrophil cytoplasmic antibody-associated vasculitis and predict prognosis: a proof of concept study. Kidney Int. Rep. 8, 871\u2013883 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1081_CR143","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.4049\/jimmunol.160.7.3602","volume":"160","author":"BR L\u00fadv\u00edksson","year":"1998","unstructured":"L\u00fadv\u00edksson, B. R. et al. Active Wegener\u2019s granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J. Immunol. 160, 3602\u20133609 (1998).","journal-title":"J. Immunol."},{"key":"1081_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1428","volume":"11","author":"C Agosto-Burgos","year":"2022","unstructured":"Agosto-Burgos, C. et al. The frequency of Treg subsets distinguishes disease activity in ANCA vasculitis. Clin. Transl. Immunol. 11, e1428 (2022).","journal-title":"Clin. Transl. Immunol."},{"key":"1081_CR145","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","volume":"388","author":"J Tuttle","year":"2023","unstructured":"Tuttle, J. et al. A phase 2 trial of peresolimab for adults with rheumatoid arthritis. N. Engl. J. Med. 388, 1853\u20131862 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1081_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032975","volume":"24","author":"S Hakroush","year":"2023","unstructured":"Hakroush, S. & Tampe, B. Association between loss of immune checkpoint programmed cell death protein 1 and active ANCA-associated renal vasculitis. Int. J. Mol. Sci. 24, 2975 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1081_CR147","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004660","volume":"10","author":"P Anton-Pampols","year":"2024","unstructured":"Anton-Pampols, P. et al. Immune checkpoint molecules performance in ANCA vasculitis. RMD Open 10, e004660 (2024).","journal-title":"RMD Open"},{"key":"1081_CR148","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s10238-022-00908-y","volume":"23","author":"J Singh","year":"2023","unstructured":"Singh, J. et al. Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis. Clin. Exp. Med. 23, 1801\u20131813 (2023).","journal-title":"Clin. Exp. Med."},{"key":"1081_CR149","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010256","volume":"24","author":"M d\u2019Alessandro","year":"2022","unstructured":"d\u2019Alessandro, M. et al. PD1, CTLA4 and TIGIT expression on T and NK cells in granulomatous diseases: sarcoidosis and ANCA-associated vasculitis. Int. J. Mol. Sci. 24, 256 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1081_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25466-x","volume":"12","author":"JY Pyo","year":"2022","unstructured":"Pyo, J. Y. et al. Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Sci. Rep. 12, 21319 (2022).","journal-title":"Sci. Rep."},{"key":"1081_CR151","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/ard-2022-222479","volume":"82","author":"G Gamerith","year":"2023","unstructured":"Gamerith, G. et al. Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission. Ann. Rheum. Dis. 82, 253\u2013261 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1081_CR152","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature14468","volume":"523","author":"EF McKinney","year":"2015","unstructured":"McKinney, E. F., Lee, J. C., Jayne, D. R. W., Lyons, P. A. & Smith, K. G. C. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523, 612\u2013616 (2015).","journal-title":"Nature"},{"key":"1081_CR153","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/nm.2130","volume":"16","author":"EF McKinney","year":"2010","unstructured":"McKinney, E. F. et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat. Med. 16, 586\u2013591 (2010).","journal-title":"Nat. Med."},{"key":"1081_CR154","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1136\/ard.2005.046219","volume":"65","author":"J-SF Sanders","year":"2006","unstructured":"Sanders, J.-S. F., Huitma, M. G., Kallenberg, C. G. M. & Stegeman, C. A. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse. Ann. Rheum. Dis. 65, 1484\u20131489 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"1081_CR155","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/S0140-6736(03)12269-6","volume":"361","author":"A Woywodt","year":"2003","unstructured":"Woywodt, A. et al. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 361, 206\u2013210 (2003).","journal-title":"Lancet"},{"key":"1081_CR156","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1002\/art.24957","volume":"60","author":"MD Morgan","year":"2009","unstructured":"Morgan, M. D. et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheumatism 60, 3493\u20133500 (2009).","journal-title":"Arthritis Rheumatism"},{"key":"1081_CR157","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1093\/eurheartj\/ehp078","volume":"30","author":"AM Leone","year":"2009","unstructured":"Leone, A. M. et al. From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells. Eur. Heart J. 30, 890\u2013899 (2009).","journal-title":"Eur. Heart J."},{"key":"1081_CR158","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1044-8","volume":"18","author":"B Wilde","year":"2016","unstructured":"Wilde, B. et al. Endothelial progenitor cells are differentially impaired in ANCA-associated vasculitis compared to healthy controls. Arthritis Res. Ther. 18, 147 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"1081_CR159","doi-asserted-by":"publisher","DOI":"10.1155\/ijne\/3133057","volume":"2025","author":"L Baas","year":"2025","unstructured":"Baas, L. et al. Biomarkers detecting the activity of ANCA-associated vasculitis: a systematic literature review. Int. J. Nephrol. 2025, 3133057 (2025).","journal-title":"Int. J. Nephrol."},{"key":"1081_CR160","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.trre.2018.10.001","volume":"33","author":"C Dendle","year":"2019","unstructured":"Dendle, C., Mulley, W. R. & Holdsworth, S. Can immune biomarkers predict infections in solid organ transplant recipients? A review of current evidence. Transpl. Rev. 33, 87\u201398 (2019).","journal-title":"Transpl. Rev."},{"key":"1081_CR161","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.3399\/bjgp20X713981","volume":"71","author":"F Hamilton","year":"2021","unstructured":"Hamilton, F., Arnold, D. & Payne, R. Association of prior lymphopenia with mortality in pneumonia: a cohort study in UK primary care. Br. J. Gen. Pract. 71, e148\u2013e156 (2021).","journal-title":"Br. J. Gen. Pract."},{"key":"1081_CR162","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1093\/rheumatology\/keac716","volume":"62","author":"MA Podest\u00e0","year":"2023","unstructured":"Podest\u00e0, M. A. et al. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study. Rheumatology 62, 2850\u20132854 (2023).","journal-title":"Rheumatology"},{"key":"1081_CR163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002685","volume":"15","author":"M Warny","year":"2018","unstructured":"Warny, M., Helby, J., Nordestgaard, B. G., Birgens, H. & Bojesen, S. E. Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Med. 15, e1002685 (2018).","journal-title":"PLoS Med."},{"key":"1081_CR164","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1097\/TP.0000000000000650","volume":"99","author":"M Ravaioli","year":"2015","unstructured":"Ravaioli, M. et al. Immunosuppression modifications based on an immune response assay: results of a randomized, controlled trial. Transplantation 99, 1625\u20131632 (2015).","journal-title":"Transplantation"},{"key":"1081_CR165","unstructured":"Odler, B. et al. Torque teno virus as a potential biomarker for assessment of immunocompetence in patients with ANCA-associated vasculitis. ACR Meeting Abstracts https:\/\/acrabstracts.org\/abstract\/torque-teno-virus-as-a-potential-biomarker-for-assessment-of-immunocompetence-in-patients-with-anca-associated-vasculitis\/ (2023)."},{"key":"1081_CR166","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1111\/ajt.15810","volume":"20","author":"K Doberer","year":"2020","unstructured":"Doberer, K. et al. Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients-a prospective observational trial. Am. J. Transpl. 20, 2081\u20132090 (2020).","journal-title":"Am. J. Transpl."},{"key":"1081_CR167","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1122972","volume":"14","author":"V Satrapova","year":"2023","unstructured":"Satrapova, V. et al. Biomarkers of fibrosis, kidney tissue injury and inflammation may predict severity and outcome of renal ANCA-associated vasculitis. Front. Immunol. 14, 1122972 (2023).","journal-title":"Front. Immunol."},{"key":"1081_CR168","doi-asserted-by":"publisher","first-page":"F1927","DOI":"10.1152\/ajprenal.00310.2007","volume":"293","author":"J-SF Sanders","year":"2007","unstructured":"Sanders, J.-S. F. et al. Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis. Am. J. Physiol. Renal Physiol 293, F1927\u2013F1934 (2007).","journal-title":"Am. J. Physiol. Renal Physiol"},{"key":"1081_CR169","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/ckj\/sfaa043","volume":"14","author":"J Villacorta","year":"2021","unstructured":"Villacorta, J. et al. Urinary soluble CD163 as a biomarker of disease activity and relapse in antineutrophil cytoplasm antibody-associated glomerulonephritis. Clin. Kidney J. 14, 212\u2013219 (2021).","journal-title":"Clin. Kidney J."},{"key":"1081_CR170","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne, D. R. W., Merkel, P. A., Schall, T. J. & Bekker, P. Avacopan for the treatment of ANCA-associated vasculitis. N. Engl. J. Med. 384, 599\u2013609 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1081_CR171","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/BOR.0000000000000491","volume":"30","author":"M Bonelli","year":"2018","unstructured":"Bonelli, M. & Scheinecker, C. How does abatacept really work in rheumatoid arthritis? Curr. Opin. Rheumatol. 30, 295\u2013300 (2018).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1081_CR172","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford, C. A. et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 69, 837\u2013845 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1081_CR173","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1093\/rheumatology\/keab827","volume":"61","author":"VR Reddy","year":"2022","unstructured":"Reddy, V. R. et al. Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab? Rheumatology 61, 2894\u20132904 (2022).","journal-title":"Rheumatology"},{"key":"1081_CR174","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-083277","volume":"14","author":"DP McGovern","year":"2024","unstructured":"McGovern, D. P. et al. Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas. BMJ Open. 14, e083277 (2024).","journal-title":"BMJ Open."},{"key":"1081_CR175","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002742","volume":"9","author":"L Ostendorf","year":"2023","unstructured":"Ostendorf, L. et al. Daratumumab for the treatment of refractory ANCA-associated vasculitis. RMD Open. 9, e002742 (2023).","journal-title":"RMD Open."},{"key":"1081_CR176","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","volume":"21","author":"C Rolin","year":"2024","unstructured":"Rolin, C., Zimmer, J. & Seguin-Devaux, C. Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases. Cell Mol. Immunol. 21, 643\u2013661 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"1081_CR177","doi-asserted-by":"publisher","first-page":"114071","DOI":"10.1016\/j.ejca.2024.114071","volume":"204","author":"M Subklewe","year":"2024","unstructured":"Subklewe, M. et al. Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study. Eur. J. Cancer 204, 114071\u00a0(2024).","journal-title":"Eur. J. Cancer"},{"key":"1081_CR178","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"1081_CR179","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/ard-2023-224875","volume":"83","author":"D Lodka","year":"2024","unstructured":"Lodka, D. et al. CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury. Ann. Rheum. Dis. 83, 499\u2013507 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1081_CR180","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","volume":"84","author":"I Minopoulou","year":"2025","unstructured":"Minopoulou, I. et al. Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis. Ann. Rheum. Dis. 84, e4\u2013e7 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1081_CR181","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.ard.2025.04.029","volume":"84","author":"L Uhlmann","year":"2025","unstructured":"Uhlmann, L. et al. Effective use of anti-CD19 chimeric antigen receptor T cells in a case of treatment-resistant granulomatosis with polyangiitis. Ann. Rheum. Dis. 84, 1280\u20131283 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1081_CR182","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1016\/j.ekir.2025.05.016","volume":"10","author":"CR Schultze-Florey","year":"2025","unstructured":"Schultze-Florey, C. R. et al. Point-of-care anti-CD19-CAR T-cell therapy induces renal remission in refractory myeloperoxidase-antineutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int. Rep. 10, 2491\u20132493 (2025).","journal-title":"Kidney Int. Rep."},{"key":"1081_CR183","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1093\/rheumatology\/keae518","volume":"64","author":"ME Free","year":"2025","unstructured":"Free, M. E. Emerging cell therapies in the vasculitis field. Rheumatology 64, i11\u2013i14 (2025).","journal-title":"Rheumatology"},{"key":"1081_CR184","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.796640","volume":"12","author":"S Fuchs","year":"2022","unstructured":"Fuchs, S., Scheffschick, A., Gunnarsson, I. & Brauner, H. Natural killer cells in anti-neutrophil cytoplasmic antibody-associated vasculitis \u2014 a review of the literature. Front. Immunol. 12, 796640 (2022).","journal-title":"Front. Immunol."},{"key":"1081_CR185","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0851-7","volume":"17","author":"W Merkt","year":"2015","unstructured":"Merkt, W. et al. Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage. Arthritis Res. Ther. 17, 337 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"1081_CR186","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2054-0","volume":"21","author":"D Urlaub","year":"2019","unstructured":"Urlaub, D. et al. Activation of natural killer cells by rituximab in granulomatosis with polyangiitis. Arthritis Res. Ther. 21, 277 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"1081_CR187","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfab250","volume":"37","author":"M Casal Moura","year":"2022","unstructured":"Casal Moura, M., Fervenza, F. C., Specks, U. & Sethi, S. Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol. Dial. Transpl. 37, 1710\u20131721 (2022).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1081_CR188","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/ndt\/gfv336","volume":"31","author":"A Kronbichler","year":"2016","unstructured":"Kronbichler, A. et al. Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis. Nephrol. Dial. Transpl. 31, 930\u2013936 (2016).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1081_CR189","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K De Groot","year":"2005","unstructured":"De Groot, K. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 2461\u20132469 (2005).","journal-title":"Arthritis Rheum."},{"key":"1081_CR190","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K de Groot","year":"2009","unstructured":"de Groot, K. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 150, 670\u2013680 (2009).","journal-title":"Ann. Intern. Med."},{"key":"1081_CR191","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2215\/CJN.03950412","volume":"8","author":"DO Bunch","year":"2013","unstructured":"Bunch, D. O. et al. Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. Clin. J. Am. Soc. Nephrol. 8, 382\u2013391 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1081_CR192","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/acr2.11366","volume":"4","author":"PA Monach","year":"2022","unstructured":"Monach, P. A. et al. Serum biomarkers of disease activity in longitudinal assessment of patients with ANCA-associated vasculitis. ACR Open. Rheumatol. 4, 168\u2013176 (2022).","journal-title":"ACR Open. Rheumatol."},{"key":"1081_CR193","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3899\/jrheum.120879","volume":"40","author":"JG Lieberthal","year":"2013","unstructured":"Lieberthal, J. G. et al. Urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. J. Rheumatol. 40, 674\u2013683 (2013).","journal-title":"J. Rheumatol."},{"key":"1081_CR194","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1681\/ASN.2021030382","volume":"32","author":"SM Moran","year":"2021","unstructured":"Moran, S. M. et al. The clinical application of urine soluble CD163 in ANCA-associated vasculitis. J. Am. Soc. Nephrol. 32, 2920\u20132932 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1081_CR195","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1681\/ASN.0000000000000311","volume":"35","author":"L Prskalo","year":"2024","unstructured":"Prskalo, L. et al. Urinary CD4+ T cells predict renal relapse in ANCA-associated vasculitis. J. Am. Soc. Nephrol. 35, 483\u2013494 (2024).","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01081-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01081-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01081-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:02:26Z","timestamp":1784548946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01081-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":195,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1081"],"URL":"https:\/\/doi.org\/10.1038\/s41581-026-01081-1","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"21 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.D.S. has received honoraria from Vifor as a speaker and consultant. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}